Houston Methodist Neurological Institute researchers from the department of neurosurgery
Read moreHome »
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
NEW YORK–(BUSINESS WIRE) November 23, 2020 — Pfizer Inc. (NYSE:
Read moreMerck Presents Three-Year Survival Data for Keytruda (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With Keytruda in Advanced Non‑Small Cell Lung Cancer
KENILWORTH, N.J.–(BUSINESS WIRE) October 16, 2020 — Merck (NYSE: MRK),
Read more